Nabi-HB-SC: Nabi-HB Administered Subcutaneously in Patients With Hepatitis B Virus Post Liver Transplantation
Study Details
Study Description
Brief Summary
A phase 3, multicenter, open label study to assess the safety and efficacy of Nabi-HB, administered subcutaneously in patients with Hepatitis B Virus Associated Liver Disease who underwent liver transplantation.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Phase 3 |
Detailed Description
This is a phase 3 prospective, single arm open label study to be conducted t approximately 4 study sited located in th e USA. Approximately 25 HBV DNA negative patients who underwent liver transplant at least one year prior, due to chronic hepatitis B infection will bwe eligible for study participation. The study consist of a total of 16 study visit and the duration of participation will be 20 weeks for each patients. Patients will be converted from the intravenous standard HBIG to Nabi-HB subcutaneous administration according to the individual scheduled dosing interval.
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Experimental: Arm One: Nabi-HB All subjects will be administered Nabi HB Subcutaneously |
Biological: Nabi-HB
Hepatitis b Immune Globulin (Human)(Nabi-HB) 312 IU/L per dose administered subcutaneously.
Dosage will be according to each patients body weight, as follow:
< 75 kg: 500 IU weekly ( may be increase to 1,000 IU weekly if anti-HBs levels are <150 IU/ML > 75 Kg: 1,000 IU weekly
Other Names:
|
Outcome Measures
Primary Outcome Measures
- To evaluate the efficacy of Nabi-HB administered subcutaneously weekly for a total of 14 weeks in patients who previously underwent a liver transplant. Levels will provide evidence if effective anti-HB levels >150 IU/ML can be maintained. [14 weeks]
Secondary Outcome Measures
- To evaluate the safety of Nabi-HB administered subcutaneously weekly for a total of 14 weeks. [14 weeks]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Male or female patients 18 years old or older as of visit one.
-
If female is not trying to conserve, not lactating, and has a negative serum pregnancy test and use an acceptable method of contraception or be at least one year post-menopausal or surgically sterile.
-
Able to provide written informed consent.
-
First time liver transplant recipient.
-
Primary, single organ recipient (deceased donor <65 years old).
-
receive regular long-term HBIG prophylaxis with stabilized HBIG dosage and administration intervals.
-
Have negative quantifiable HBV-DNA and HBsAg results prior to dosing at visit 2.
-
Following the last IV administration of HBIG, have a baseline serum anti-HBs level of
150 IU/ML prior to dosing at visit 2.
Exclusion Criteria
-
Positive HCV or HIV test results.
-
Unexplained elevated liver function tests.
-
Serum creatinine level >2.0 times the upper limit of normal.
-
life expectancy <6 months.
-
liver transplantation with ongoing acute rejection episode. Donor liver that was from a hepatitis Bor C positive donor. Underwent a liver transplant <12 months prior to visit 1.
-
Know history of cancer, suspected cancer, or cancer therapy within 12 months.
-
History of autoimmune disease.
-
History/current evidence of coagulation disorder, severe cardiac disease, unhealed gastric or duodenal ulcer, or other significant disease.
-
Evidence of any other unresolved infection and any unresolved opportunistic infection requiring treatment.
-
Known immunoglobulin A deficiency.
-
History of use of immunosupressive or immunomodulatory drug within 3 month prior to visit 1. (except low dose glucocorticoid therapy, <10 mg of prednisone or equivalent per day.)
-
received and investigational drug 30 days prior to visit 1.
-
use of plasma preparations or other immunoglobulins during the study.
-
Know intolerance to proteins of human origin, immunoglobulin, or comparable products.
-
Evidence of alcohol and/or drug abuse within 6 month of visit 2 or inability/unwillingness to abstain from alcohol for the duration of the study.
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Biotest Pharmaceuticals Corporation
Investigators
- Study Director: Shailesh Chavan, MD, Sponsor GmbH
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 4210